The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
The congress aims at emphasizing on the most recent trends, advancements in the field of Obstetrics & Gynaecology
Medway setup a state-of-the-art Heart Institute in Chennai
This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy
Ecolab’s continued leadership position on renowned sustainability indices demonstrates the company’s record of advancing sustainable growth
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
NEIAFMR to be developed as the national hub for folk medicine
Furthering cell therapy ambition across oncology and autoimmune diseases
Subscribe To Our Newsletter & Stay Updated
